Open-label, Phase I Dose-escalation Clinical Study of the Safety, Tolerability and Pharmacokinetics of Single Subcutaneus Dose of BCD-085, Monoclonal Antibody Against IL-17, in Healthy Subjects

Trial Profile

Open-label, Phase I Dose-escalation Clinical Study of the Safety, Tolerability and Pharmacokinetics of Single Subcutaneus Dose of BCD-085, Monoclonal Antibody Against IL-17, in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs BCD 085 (Primary)
  • Indications Autoimmune disorders
  • Focus First in man; Pharmacokinetics
  • Sponsors Biocad
  • Most Recent Events

    • 11 Jun 2016 Results presented at the 17th Annual Congress of the European League Against Rheumatism
    • 12 Jan 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top